NewLink in $1 billion deal with Roche to develop cancer drug

NewLink in $1 billion deal with Roche to develop cancer drug

(Reuters) – NewLink Genetics Corp (NLNK.O) said it entered into an agreement with Roche Holding AG (ROG.VX) to develop NewLink’s cancer immunotherapy, making the Ebola vaccine developer eligible to receive over 350 billion in milestone payments.

NewLink’s shares jumped nearly 30 percent before the bell on Monday.

Immunotherapies are a class of drugs designed to help the body’s own immune system fend off disease.

Iowa-based NewLink, which holds the commercial license for an Ebola vaccine developed by the Canadian government, will receive an upfront payment of 0 million under the worldwide licensing deal from Genentech, a unit of Switzerland’s Roche.

Under the agreement, the companies will develop a NewLink inhibitor, NLG919, that is designed to disrupt the mechanism by which tumors evade the patients immune system.

Genentech will fund future research, development, manufacturing and marketing costs related to the drug, NewLink said.

NLG919 is currently in early-stage testing for use in solid tumors. The company is currently testing a similar inhibitor, indoximod, in mid-stage studies in patients with breast and prostate cancer.

NewLink’s shares were up 30 percent at .20. They rose 62 percent in the past week.

(Reporting by Natalie Grover in Bangalore; Editing by Saumyadeb Chakrabarty)

Read the original here:
feeds.reuters

Healthy Living News From around The Web
NewLink in $1 billion deal with Roche to develop cancer drug – Yahoo News

Google+

Dopps Chiropractic
4746 S. Broadway
WichitaKs 67216

(316) 522-1122
http://ift.tt/14R1IJ3
Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s